GE HealthCare Technologies is trading higher in extended hours following the announcement that its StarGuide GX 4D SPECT/CT system has been submitted for FDA 510(k) clearance. This regulatory milestone, which follows the system's recent CE Mark approval in Europe, highlights the company's progress in advancing its molecular imaging technology. While the stock faced mild pressure during the regular session alongside peer Koninklijke Philips, which fell 1.7%, the positive momentum from the FDA submission appears to be driving investor interest after the closing bell.